Patients that schedule regular mammograms could easily be encouraged to screen for melanoma via self-skin examination when given instructions at their breast cancer screenings, according to a recent study. This type of intervention program could be an effective strategy to increase skin cancer awareness.
A pregnancy-associated melanoma (PAM) prognosis does not appear to be worse than melanoma in non-pregnant controls, researchers reported at EADV. Nonetheless, measures should be taken to protect the fetus in the treatment and imaging of PAM.
With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.
Checkpoint inhibitors have clearly changed the prognosis of melanoma, yet the search for evidence-based answers to these and other questions regarding their use continues, experts report at EADV this week.
The European Academy of Dermatology and Venerology (EADV) 2018 meeting takes this week in Paris. Visit our EADV conference news site to follow the developments from Paris.
Combination that extends survival in BRAF-mutant metastatic melanoma gains FDA approval.
Monitoring changes in patients with melanoma can be tricky. Some changes present slowly and in tiny ways. Using imaging technologies to track these changes can help achieve an accurate diagnosis.
Nearly half of patients at an outpatient primary care clinic elected to learn about genomic testing to assess their risk of melanoma.
Pediatric melanomas are often misdiagnosed by physicians. Adolescents have a more aggressive disease course than children and are treated with adult protocols leading to chronic morbidity.
The combination of encorafenib plus binimetinib significantly improved overall survival versus vemurafenib in patients with BRAF-mutant melanoma, updated results of the randomized, phase three COLUMBUS trial show.